Laschak et al. BMC Cancer 2012, 12:130 http://www.biomedcentral.com/1471-2407/12/130 Mammalian Two-Hybrid System described in Material and Methods. Results are mean values of three independent experiments performed in quadruplicates. (DOC 20 kb). Additional file 2: Figure 2S: NO does not influence hormone- induced nuclear translocation of AR-EosFP in DU-145. Complementary data to experiment presented in Figure 4. (TIFF 1541 kb). Acknowledgements This work was supported by grants from the Deutsche Forschungsgemeinschaft (HE 6078), Action Lions Vaincre le Cancer, Luxembourg (MVC) and the International Graduate School in Molecular Medicine Ulm (ML). The authors thank K. Dengler-Wupperfeld and S. Schmidt for skillful technical assistance. Author details 1Institute for General Zoology and Endocrinology, Ulm University, Albert Einstein Allee 23, 89069 Ulm, Germany. 2Department of Urology, Ulm University, Prittwitzstrasse 43, 89075, Ulm, Germany. Authors’ contributions ML, K-D S and MVC conceived the study; ML, WS, AH performed the experiments, MS AJS contributed to data analysis; MVC, K-D S, AJS, MS wrote the paper. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 4 November 2011 Accepted: 30 March 2012 Published: 30 March 2012 References 1. Burgaud JL, Riffaud JP, Del Soldato P: Nitric-oxide releasing molecules: A new class of drugs with several major indications. Curr Pharm Design 2002, 8:201-213. 2. Pavlos CM, Xu H, Toscano JP: Photosensitive precursors to nitric oxide. Curr Top Med Chem 2005, 5:637-647. 3. Kanwar JR, Kanwar RK, Burrow H, Baratchi S: Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem 2009, 16:2373-2394. 4. Ahmad R, Rasheed Z, Ahsan H: Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009, 31:388-396. 5. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ: JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol 2010, 62:145-151. 6. McMurtry V, Saavedra JE, Nieves-Alicea R, Simeone AM, Keefer LK, Tari AM: JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. Int J Oncol 2011, 38:963-971. 7. Cantuaria G, Magalhaes A, Angioli R, Mendez L, Mirhashemi R, Wang J, Wang P, Penalver M, Averette H, Braunschweiger P: Antitumor activity of a novel glyco-nitric oxide conjugate in ovarian carcinoma. Cancer 2000, 88:381-388. 8. Stevens EV, Carpenter AW, Shin JH, Liu J, Der CJ, Schoenfisch MH: Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol Pharm 2010, 7:775-785. 9. Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H, Baba H: Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res 2010, 8:1152-1163. 10. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK: Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004, 172:338-344. 11. Huguenin S, Fleury-Feith J, Kheuang L, Jaurand MC, Bolla M, Riffaud JP, Chopin DK, Vacherot F: Nitrosulindac (NCX 1102): a new nitric oxide- donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits Page 9 of 10 proliferation and induces apoptosis in human prostatic epithelial cell lines. Prostate 2004, 61:132-141. 12. Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics. CA Cancer J Clin 2010, 60:277-300. 13. Kirby M, Hirst C, Crawford ED: Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011, 65:1180-1192. 14. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9:401-406. 15. Hobisch Z, Culig C, Radmayr G, Bartsch H, Klocker A, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995, 55:3068-3072. 16. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996, 28:129-135. 17. Cronauer MV, Schulz WA, Burchardt T, Anastasiadis AG, de la Taille A, Ackermann R, Burchardt M: The androgen receptor in hormone-refractory prostate cancer: relevance of different mechanisms of androgen receptor signaling (Review). Int J Oncol 2003, 23:1095-1102. 18. Céraline J, Cruchant MD, Erdmann E, Erbs P, Kurtz JE, Duclos B, Jacqmin D, Chopin D, Bergerat JP: Constitutive activation of the androgen receptor by a point mutation in the hinge region: A new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004, 108:152-157. 19. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M: Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007, 67:9001-9005. 20. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008, 68:5469-5477. 21. Dehm SM, Tindall DJ: Alternatively spliced androgen receptor variants. Endocr Relat Cancer 2011, 18:R183-R196. 22. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, Suschek CV, Burchardt M, Kleinert H, Wiedenmann J, Sies H, Ackermann R, Kröncke KD: Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 2007, 26:1875-1884. 23. Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK: JS- K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2003, 2:409-417. 24. Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC: JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood 2007, 110:709-718. 25. Chen MW, Vacherot F, De La Taille A, Gil-Diez-De-Medina S, Shen R, Friedman RA, Burchardt M, Chopin DK, Buttyan R: The emergence of protocadherin-PC expression during the acquisition of apoptosis- resistance by prostate cancer cells. Oncogene 2002, 21:7861-7871. 26. Schütz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV, Schrader M: Inhibition of glycogen synthase kinase-3β counteracts ligand- independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One 2011, 6:e25341. 27. Cronauer MV, Schulz WA, Ackermann R, Burchardt M: Effects of WNT/β- catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncology 2005, 26:1033-1040. 28. Laschak M, Bechtel M, Spindler KD, Hessenauer A: Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines. Int J Mol Med 2011, 28:645-651. 29. Rinnab L, Schütz SV, Jeannine Diesch J, Schmid E, Küfer R, Hautmann RE, Spindler K-D, Cronauer MV: Inhibiton of Glycogen-Synthase Kinase-3 (GSK) in Androgen Responsive Prostate Cancer Cell Lines - Are GSK- Inhibitors Therapeutically Useful? Neoplasia 2008, 10:624-634.